J Attal1, B Cabarrou2, T Valentin3, J P Nesseler4, E Stoeckle5, A Ducassou6, T Filleron2, S Le Guellec7, B Boulet8, G Vogin9,10, G Ferron11, E Cohen-Jonathan Moyal6,12,13, M Delannes6, C Chevreau3. 1. Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. justine.attal@hotmail.fr. 2. Department of Biostatistics, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. 3. Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. 4. Department of Radiation Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 5. Department of Surgery, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. 6. Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. 7. Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. 8. Department of Radiology, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. 9. Department of Radiation Oncology, institut de cancérologie de Lorraine, 6 avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France. 10. UMR 7365 CNRS-Université de Lorraine, IMoPA, Vandoeuvre-les-Nancy, France. 11. Department of Surgery, Institut Universitaire du Cancer de Toulouse-Oncopôle, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France. 12. INSERM U1037, Cancer Research Center of Toulouse (CRCT), 31000, Toulouse, France. 13. Université Toulouse III Paul Sabatier, 31000, Toulouse, France.
Abstract
PURPOSE: Patients with locally advanced grade 2-3 extremity/truncal soft tissue sarcomas (STS) are at high risk of recurrence. The objective of this study was to assess the efficacy and feasibility of neoadjuvant concurrent chemoradiotherapy (cCRT) in selected grade 2-3 patients with limb or trunk wall STS, and to compare this schedule to a sequential approach combining neoadjuvant chemotherapy and adjuvant radiotherapy. METHODS: We retrospectively included patients who underwent neoadjuvant cCRT at two comprehensive cancer centers from 1992-2016. We then compared these results to those of patients treated with preoperative chemotherapy and postoperative radiotherapy from a third comprehensive cancer center with a propensity score matched analysis. RESULTS: A total of 53 patients were treated by neoadjuvant cCRT; 58 patients could be matched with 29 patients in each treatment group after propensity score matching. Disease-free survival and overall survival at 5 years were 54.9 and 63.5%, respectively with neoadjuvant cCRT, with no significant difference when compared to the sequential treatment group. R0 resection rate was higher (90.9 vs 44.8%, p < 0.01) in the cCRT group than in the sequential treatment group during a shorter therapeutic sequence (118 vs 210.5 days, p < 0.01), with no impact on the surgical procedure or postoperative complications. CONCLUSION: cCRT is feasible with acceptable immediate and late toxicities. It could facilitate surgery by increasing the R0 resection rate and improve patient compliance by shortening the therapeutic sequence.
PURPOSE: Patients with locally advanced grade 2-3 extremity/truncal soft tissue sarcomas (STS) are at high risk of recurrence. The objective of this study was to assess the efficacy and feasibility of neoadjuvant concurrent chemoradiotherapy (cCRT) in selected grade 2-3 patients with limb or trunk wall STS, and to compare this schedule to a sequential approach combining neoadjuvant chemotherapy and adjuvant radiotherapy. METHODS: We retrospectively included patients who underwent neoadjuvant cCRT at two comprehensive cancer centers from 1992-2016. We then compared these results to those of patients treated with preoperative chemotherapy and postoperative radiotherapy from a third comprehensive cancer center with a propensity score matched analysis. RESULTS: A total of 53 patients were treated by neoadjuvant cCRT; 58 patients could be matched with 29 patients in each treatment group after propensity score matching. Disease-free survival and overall survival at 5 years were 54.9 and 63.5%, respectively with neoadjuvant cCRT, with no significant difference when compared to the sequential treatment group. R0 resection rate was higher (90.9 vs 44.8%, p < 0.01) in the cCRT group than in the sequential treatment group during a shorter therapeutic sequence (118 vs 210.5 days, p < 0.01), with no impact on the surgical procedure or postoperative complications. CONCLUSION: cCRT is feasible with acceptable immediate and late toxicities. It could facilitate surgery by increasing the R0 resection rate and improve patient compliance by shortening the therapeutic sequence.
Authors: Dian Wang; Qiang Zhang; Burton L Eisenberg; John M Kane; X Allen Li; David Lucas; Ivy A Petersen; Thomas F DeLaney; Carolyn R Freeman; Steven E Finkelstein; Ying J Hitchcock; Manpreet Bedi; Anurag K Singh; George Dundas; David G Kirsch Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: P G Casali; N Abecassis; H T Aro; S Bauer; R Biagini; S Bielack; S Bonvalot; I Boukovinas; J V M G Bovee; T Brodowicz; J M Broto; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; M Eriksson; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; B Kasper; K Kopeckova; D A Krákorová; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: Alessandro Gronchi; Stefano Ferrari; Vittorio Quagliuolo; Javier Martin Broto; Antonio Lopez Pousa; Giovanni Grignani; Umberto Basso; Jean-Yves Blay; Oscar Tendero; Robert Diaz Beveridge; Virginia Ferraresi; Iwona Lugowska; Domenico Franco Merlo; Valeria Fontana; Emanuela Marchesi; Davide Maria Donati; Elena Palassini; Emanuela Palmerini; Rita De Sanctis; Carlo Morosi; Silvia Stacchiotti; Silvia Bagué; Jean Michelle Coindre; Angelo Paolo Dei Tos; Piero Picci; Paolo Bruzzi; Paolo Giovanni Casali Journal: Lancet Oncol Date: 2017-05-09 Impact factor: 41.316
Authors: Alessandro Gronchi; Salvatore Lo Vullo; Chiara Colombo; Paola Collini; Silvia Stacchiotti; Luigi Mariani; Marco Fiore; Paolo Giovanni Casali Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: Gunar K Zagars; Matthew T Ballo; Peter W T Pisters; Raphael E Pollock; Shreyaskumar R Patel; Robert S Benjamin; Harry L Evans Journal: Cancer Date: 2003-05-15 Impact factor: 6.860
Authors: V Bramwell; J Rouesse; W Steward; A Santoro; H Schraffordt-Koops; J Buesa; W Ruka; J Priario; T Wagener; M Burgers Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544